Search

Your search keyword '"Wadhwa, Ridhima"' showing total 7 results
Start Over Author "Wadhwa, Ridhima" Publisher wiley
7 results on '"Wadhwa, Ridhima"'

1. Aim2 suppresses cigarette smoke‐induced neutrophil recruitment, neutrophil caspase‐1 activation and anti‐Ly6G‐mediated neutrophil depletion

Author

Donovan, Chantal, primary, Kim, Richard Y, additional, Galvao, Izabela, additional, Jarnicki, Andrew G, additional, Brown, Alexandra C, additional, Jones‐Freeman, Bernadette, additional, Gomez, Henry M, additional, Wadhwa, Ridhima, additional, Hortle, Elinor, additional, Jayaraman, Ranjith, additional, Khan, Haroon, additional, Pickles, Sophie, additional, Sahu, Priyanka, additional, Chimankar, Vrushali, additional, Tu, Xiaofan, additional, Ali, Md Khadem, additional, Mayall, Jemma R, additional, Nguyen, Duc H, additional, Budden, Kurtis F, additional, Kumar, Vinod, additional, Schroder, Kate, additional, Robertson, Avril AB, additional, Cooper, Matthew A, additional, Wark, Peter AB, additional, Oliver, Brian G, additional, Horvat, Jay C, additional, and Hansbro, Philip M, additional

Published
2022
Full Text
View/download PDF

2. Pulmonary Bioadhesive Drug Delivery Systems and Their Applications

Author

Wadhwa, Ridhima, primary, Bharathala, Subhashini, additional, Aggarwal, Taru, additional, Sehgal, Nikita, additional, Kumar, Nitesh, additional, Gupta, Gaurav, additional, Chellappan, Dinesh Kumar, additional, Maurya, Pawan Kumar, additional, Pinto, Terezinha De Jesus Andreoli, additional, Collet, Trudi, additional, Dureja, Harish, additional, Hansbro, Philip M., additional, and Dua, Kamal, additional

Published
2020
Full Text
View/download PDF

3. Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

Author

Chellappan, Dinesh K., primary, Yee, Lim W., additional, Xuan, Kong Y., additional, Kunalan, Kishen, additional, Rou, Lim C., additional, Jean, Leong S., additional, Ying, Lee Y., additional, Wie, Lee X., additional, Chellian, Jestin, additional, Mehta, Meenu, additional, Satija, Saurabh, additional, Singh, Sachin K., additional, Gulati, Monica, additional, Dureja, Harish, additional, Da Silva, Mateus Webba, additional, Tambuwala, Murtaza M., additional, Gupta, Gaurav, additional, Paudel, Keshav R., additional, Wadhwa, Ridhima, additional, Hansbro, Philip M., additional, and Dua, Kamal, additional

Published
2020
Full Text
View/download PDF

4. The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

Author

Dua, Kamal, primary, Wadhwa, Ridhima, additional, Singhvi, Gautam, additional, Rapalli, Vamshikrishna, additional, Shukla, Shakti Dhar, additional, Shastri, Madhur D., additional, Gupta, Gaurav, additional, Satija, Saurabh, additional, Mehta, Meenu, additional, Khurana, Navneet, additional, Awasthi, Rajendra, additional, Maurya, Pawan Kumar, additional, Thangavelu, Lakshmi, additional, S, Rajeshkumar, additional, Tambuwala, Murtaza M., additional, Collet, Trudi, additional, Hansbro, Philip M., additional, and Chellappan, Dinesh Kumar, additional

Published
2019
Full Text
View/download PDF

5. Identification of biomarkers and genetic approaches toward chronic obstructive pulmonary disease

Author

Wadhwa, Ridhima, primary, Aggarwal, Taru, additional, Malyla, Vamshikrishna, additional, Kumar, Nitesh, additional, Gupta, Gaurav, additional, Chellappan, Dinesh Kumar, additional, Dureja, Harish, additional, Mehta, Meenu, additional, Satija, Saurabh, additional, Gulati, Monica, additional, Maurya, Pawan Kumar, additional, Collet, Trudi, additional, Hansbro, Philip Michael, additional, and Dua, Kamal, additional

Published
2019
Full Text
View/download PDF

7. Anti-inflammatory and anticancer activities of Naringenin-loaded liquid crystalline nanoparticles in vitro.

Author

Wadhwa R, Paudel KR, Chin LH, Hon CM, Madheswaran T, Gupta G, Panneerselvam J, Lakshmi T, Singh SK, Gulati M, Dureja H, Hsu A, Mehta M, Anand K, Devkota HP, Chellian J, Chellappan DK, Hansbro PM, and Dua K

Subjects
A549 Cells, Anti-Inflammatory Agents pharmacology, Humans, Flavanones pharmacology, Nanoparticles
Abstract

In this study, we had developed Naringenin-loaded liquid crystalline nanoparticles (LCNs) and investigated the anti-inflammatory and anticancer activities of Naringenin-LCNs against human airway epithelium-derived basal cells (BCi-NS1.1) and human lung epithelial carcinoma (A549) cell lines, respectively. The anti-inflammatory potential of Naringenin-LCNs evaluated by qPCR revealed a decreased expression of IL-6, IL-8, IL-1β, and TNF-α in lipopolysaccharide-induced BCi-NS1.1 cells. The activity of LCNs was comparable to the positive control drug Fluticasone propionate (10 nM). The anticancer activity was studied by evaluating the antiproliferative (MTT and trypan blue assays), antimigratory (scratch wound healing assay, modified Boyden chamber assay, and immunoblot), and anticolony formation activity in A549 cells. Naringenin LCNs showed promising antiproliferative, antimigratory, and anticolony formation activities in A549 cells, in vitro. Therefore, based on our observations and results, we conclude that Naringenin-LCNs may be employed as a potential therapy-based intervention to ameliorate airway inflammation and to inhibit the progression of lung cancer. PRACTICAL APPLICATIONS: Naringenin was encapsulated into liquid crystalline nanoparticles, thus, attributing to their sustained-release nature. In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1β, IL-6, TNF-α, and IL-8. In addition, the Naringenin-loaded LCNs also possess potent anticancer activity, when tested in the A549 cell line, as revealed by the inhibition of proliferation and migration of cells. They also attenuated colony formation and induced apoptosis in the A549 cells. The findings from our study could form the basis for future research that may be translated into an in vivo model to validate the possible therapeutic alternative for lung cancer using Naringenin-loaded LCNs. In addition, the applications of Naringenin-loaded LCNs as an intervention would be of great interest to biological, formulation and respiratory scientists and clinicians., (© 2020 Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results